Georgia officials halted all in-state poultry sales, and the U.S. Department of Health and Human Services awarded $590 ...

The current public-health risk is low, but the CDC is watching the situation carefully and working with states to monitor ...

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1878.47 with a total volume of ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...

J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...